Literature DB >> 34295765

Factors that influence patients' views on treatment decision-making in localised kidney cancer.

Katharina Beyer1, Ravi Barod2, David Nicol, Muddassar Hussain, Mieke Van Hemelrijck1, Netty Kinsella1.   

Abstract

Entities:  

Year:  2021        PMID: 34295765      PMCID: PMC8261443          DOI: 10.21037/tau-20-1317

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


× No keyword cloud information.
The increasing number of treatment options for localised kidney cancer presents a unique challenge for both patients and clinicians during the decision-making process (1). Current treatment options for localised tumours (T1b, T2, T3), which comprise the largest group of patients, include active surveillance, surgery and minimally invasive ablative procedures (1,2). These differ with respect to morbidity and individual patient confidence with respect to long term outcomes and potential implications. International guidelines on treatment decision-making in cancer-care recognise the importance of involving patients in the treatment decision-making process (3). The American Urological Association and the NICE guidelines in the UK highlight that treatment decisions are ‘preference sensitive’ and recommend implementing shared decision-making (1,4). In order to implement this, it is first important to understand what factors influence a patient’s decision-making. We conducted a systematic review of the evidence following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (5). A computerised literature search of databases (PubMed, Cochrane) was performed to identify full text and abstracts published between 1st of January 2004 to September 2020 (). Studies were selected on the basis that: (I) they explored patient views on treatment decision-making; (II) they were of sufficient methodological quality; and (III) their findings could be translated into suggestions for supportive care.
Figure 1

Key word search terms.

Key word search terms. After screening titles and abstracts we identified 534 studies of which 22 met the inclusion criteria. Full text review of these by two authors (NK and KB) five studies were identified as relevant (). Data was extracted following a Bayesian approach where data is codified into themes and presented in a meta-aggregation generating summative statements of the evidence (6). For each identified study we extracted information on treatment decision-making factors identified by patients.
Figure 2

PRISMA.

PRISMA. One study evaluated an interdisciplinary service for renal malignancies (7), whereas another conducted an assessment of patients’/caregivers’ perception of information provided in renal cancer treatment (8). The third study used a survey to measure the patients’ decisional quality (e.g., emotional impact or knowledge of the decision to take) in patients diagnosed with localised kidney cancer (1). The fourth and fifth study developed a patient decision aid for surgical treatment and active surveillance in localised renal cancer (9). A summary of the factors identified to influence patient decision-making in these five studies is shown in . Key themes emerged around ‘Patient-related criteria’ and ‘Patient-physician interaction’. The patient-related criteria included: decisional quality and patient’s risk perception (e.g., anxiety, concerns about cancer) (1,7-9). Factors contributing to the patient-physician interaction centred around patient involvement in decision-making, perceived shared decision-making and the negative influence of paternalistic care (1,7,8).
Table 1

Summary table: factors influencing patient decision-making

Decision maker criteriaFactorsSupportive care suggestionsWhy is this important in clinical practiceRef
Patient-related criteria’Patient decisional quality: (= education level; age; patient satisfaction with care; knowledge of kidney cancer; decisional conflict; emotional impact of decision making; emotional impact of decision making)Introduce clinical decision aids to increase patient involvement and knowledge about their diseaseWill reduce decisional conflict of the patient and shared decision making; however, it does not replace counselling(1,9,10)
Patient’s risk perception: (= fear of recurrence; fatigue; anxiety; concerns about cancer; depression; aches; decreased interest in previously enjoyed activities; decreased interest in previously enjoyed events; decreased interest in previously enjoyed events; reluctance to start new relationships)Providing patients/caregivers with an electronic or written document to act as a reminder/resourceWill ensure that physicians do not omit or ‘gloss over’ important issues and patient can access information provided in a less stressful environment(8)
Educational videos and online modules before the appointmentWill prepare patients for an interactive consultation regarding their care(1)
Patient-physician interactionPatient involvement in decision making: (= interaction with different specialities; perceived shared decision making; paternalistic care, (clear) information provided by the doctor; psychological support)Interdisciplinary counselling serviceWill enable patient to receive a complete picture(7)
Provide more information about their cancer, long term follow-up and potential complicationsSetting the scene for decision making and setting patient expectations(8)
Shared decision-making modellingConsider use in reimbursement models (US) and private consultations. Increases adherence to clinical management guidelines.(1)
The five studies also identified gaps in supportive care during the decision-making process and recommended a move away from a paternalistic decision making model. Shirk (in 2018) and Moretto (in 2014) concluded that patients lack knowledge even after counselling (1,8), and consequently are heavily influenced by paternalistic care (1). To enable the patient to actively participate in their own care, Huber et al. (in 2018) introduced interdisciplinary counselling in which the patient was encouraged to attend the tumour board (i.e., Multi-Disciplinary Team meeting) (7). This led to a significant shift in treatment decision-making, with documented change in treatment decisions alongside improved satisfaction with care (7). McAlpine et al. (in 2019) developed two patient decision aids for patients with localised renal cancer, which aimed to improve decisional quality (9,10). This short review captures the complexity of decision-making purely from the patient perspective. An understanding of these factors is required to reduce paternalistic decision-making models of care and empower patients to take an equal and active part in the treatment decision-making process. However, we recommend future research of all factors influencing the treatment decision making process (e.g., physician-related factors) to increase guideline adherence, improve satisfaction of care and in particularly help to capture the complexity of decision making. The article’s supplementary files as
  8 in total

1.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.

Authors:  Börje Ljungberg; Laurance Albiges; Yasmin Abu-Ghanem; Karim Bensalah; Saeed Dabestani; Sergio Fernández-Pello; Rachel H Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Teele Kuusk; Thomas B Lam; Lorenzo Marconi; Axel S Merseburger; Thomas Powles; Michael Staehler; Rana Tahbaz; Alessandro Volpe; Axel Bex
Journal:  Eur Urol       Date:  2019-02-23       Impact factor: 20.096

2.  Kidney cancer survivorship survey of urologists and survivors: The gap in perceptions of care, but agreement on needs.

Authors:  Patricia Moretto; Michael A S Jewett; Joan Basiuk; Deborah Maskens; Christina M Canil
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

3.  Decisional Quality in Patients With Small Renal Masses.

Authors:  Joseph D Shirk; Aaron Laviana; Sylvia Lambrechts; Lorna Kwan; Casey Pagan; Amit Sumal; Christopher Saigal
Journal:  Urology       Date:  2018-03-21       Impact factor: 2.649

Review 4.  Provision of cancer information as a "support for navigating the knowledge landscape": findings from a critical interpretive literature synthesis.

Authors:  Karolina A Kazimierczak; Zoë C Skea; Mary Dixon-Woods; Vikki A Entwistle; Deb Feldman-Stewart; James M O N'dow; Sara J MacLennan
Journal:  Eur J Oncol Nurs       Date:  2012-11-17       Impact factor: 2.398

5.  Shared decision-making for the management of small renal masses - development and acceptability testing of a novel patient decision aid.

Authors:  Kristen McAlpine; Rodney H Breau; Dawn Stacey; Christopher Knee; Michael A S Jewett; Philippe D Violette; Patrick O Richard; Ilias Cagiannos; Christopher Morash; Luke T Lavallée
Journal:  Can Urol Assoc J       Date:  2020-06-16       Impact factor: 1.862

6.  Interdisciplinary counseling service for renal malignancies: a patient-centered approach to raise guideline adherence.

Authors:  Johannes Huber; Andreas Ihrig; Eva Winkler; Anette Brechtel; Hans-Christoph Friederich; Wolfgang Herzog; Martin Frank; Carsten Grüllich; Peter Hallscheidt; Martin Zeier; Sascha Pahernik; Markus Hohenfellner
Journal:  Urol Oncol       Date:  2014-10-30       Impact factor: 3.498

7.  Development and acceptability testing of a patient decision aid for individuals with localized renal masses considering surgical removal with partial or radical nephrectomy.

Authors:  Kristen McAlpine; Rodney H Breau; Dawn Stacey; Christopher Knee; Michael A S Jewett; Ilias Cagiannos; Christopher Morash; Luke T Lavallée
Journal:  Urol Oncol       Date:  2019-09-17       Impact factor: 3.498

8.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.